Scarica l'app Stockscreener
0.7033
0.00%
0.00
Precedente Chiudi:
$0.7033
Aprire:
$0.7033
Volume 24 ore:
61,681
Relative Volume:
0.34
Capitalizzazione di mercato:
$24.72M
Reddito:
-
Utile/perdita netta:
$-57.33M
Rapporto P/E:
-0.4866
EPS:
-1.4452
Flusso di cassa netto:
$-42.44M
1 W Prestazione:
+1.44%
1M Prestazione:
-4.08%
6M Prestazione:
-36.64%
1 anno Prestazione:
-83.98%
Intervallo 1D:
$0.7033
$0.7193
Intervallo di 1 settimana:
$0.675
$0.7193
Portata 52W:
$0.5655
$4.9902
Skye Bioscience Inc Stock (SKYE) Company Profile
Nome
Skye Bioscience Inc
Settore
Industria
Telefono
(858) 410-0266
Indirizzo
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE vs MOBBW, GOODO, PSNYW, SHMD, DWLD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
MOBBW
Mobilicom Limited Warrants
|
2.49 | 2.97B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
20.01 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.20 | 349.09M | 2.07B | -1.42B | -1.37B | -0.6765 |
SHMD
Schmid Group N V
|
4.72 | 358.07M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
47.37 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-06 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-06 | Downgrade | Craig Hallum | Buy → Hold |
| 2025-08-15 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | William Blair | Outperform |
| 2024-09-30 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-09 | Iniziato | Craig Hallum | Buy |
| 2024-05-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-04-12 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Skye Bioscience Inc Borsa (SKYE) Ultime notizie
Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, In - The National Law Review
Skye Bioscience, Inc. Financial Disclosures & SEC Filings - TradingView
Price to earnings forward of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView
Enterprise value to revenue forward of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView
Price to book forward of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView
Enterprise value to EBIT forward of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView
Price to sales forward of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView
Skye Bioscience, Inc. Actuals & Estimates (NASDAQ:SKYE) - TradingView
Skye Bioscience, Inc. Actuals & Estimates (FWB:09R) - TradingView
SKYE Forecast — Price Target — Prediction for 2027 - TradingView
Skye Bioscience Moves Listing to Nasdaq Capital Market - The Globe and Mail
Skye Bioscience to Move Listing to Nasdaq Capital Market After Equity Shortfall - TradingView
Skye Bioscience (NASDAQ: SKYE) shifts to Nasdaq Capital Market amid listing notices - Stock Titan
Skye Bioscience Inc (SKYE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Skye Bioscience Inc (SKYE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Skye Bioscience, Inc. Stock 12‑Month Price Target Cut to $7.33, Implies 937% Upside - TradingView
Skye Bioscience Inc (SKYE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Skye Bioscience Inc (SKYE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Skye Bioscience Inc (SKYE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Skye Bioscience Inc (SKYE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Skye Bioscience Inc (SKYE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Skye Bioscience Inc (SKYE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Skye Bioscience Inc (SKYE) Institutional Confidence - TradingKey
Piper Sandler Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Cuts Target Price to $6 - 富途牛牛
SKYE News | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill
Skye Bioscience (SKYE) Surges 5% as Key Support Holds, Resistance in FocusPut Wall - newsline.com
SKYE Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances Pipeline, Stock RisesEBITDA Margin Trends - newsline.com
SKYE Stock Chart | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill
Skye Bioscience (SKYE) Holds Near Support Amid Modest GainsDividend ETF - newsline.com
Skye Bioscience, Inc. Amends Articles of Incorporation to Increase Authorized Shares – SEC 8-K Filing May 2026 - Minichart
SKYESkye Bioscience Inc Latest SEC Filings - Finviz
Skye Bioscience Expands Authorized Shares After Shareholder Approval - TipRanks
Skye Bioscience (NASDAQ: SKYE) holders back major share authorization increase - Stock Titan
Skye Bioscience (SKYE) Tumbles 8.8% as Selling Pressure Intensifies, Support in SightFactor Rotation - The Legal Advocate
SKYE Stock Quote Price and Forecast - CNN
Skye Bioscience (SKYE) Edges Higher, Testing Resistance Near Key LevelsUpthrust Pattern - The Legal Advocate
Skye Bioscience (SKYE) Edges Higher Amid Renewed Buyer InterestNarrow Range Breakout - The Legal Advocate
Skye Bioscience (SKYE) Holds Above Support After Modest GainTrading Ideas - newsline.com
SKYE Q1 2026 Earnings: EPS Misses Estimates Amid No Revenue, Shares Edge HigherReturn On Assets - The Legal Advocate
Skye Bioscience (SKYE) Edges Higher as Support Holds, Testing Key Resistance at $0.88Volume Oscillator - The Legal Advocate
SKYE: All proposals passed, directors elected, and no stakeholder questions were raised - TradingView
SKYE Q1 2026 Earnings: EPS Slightly Below Estimates, Stock Surges 16% on Strategic ProgressMargin Guidance - The Legal Advocate
Skye Bioscience Rallies; Holiday Week Puts Focus on Tuesday - Bez Kabli
Skye Bioscience Surges 7.7%: Biotech Stock Tests Resistance at $0.81IV Percentile - newsline.com
Skye Bioscience gets approval to open second cohort in study By Investing.com - Investing.com Australia
Skye announces cohort review committee approved opening of cohort 2 based on favorable safety data from first four participants treated in cohort 1 - marketscreener.com
Skye Bioscience gets approval to open second cohort in study - Investing.com
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1 - The Manila Times
Skye Announces Cohort Review Committee Approved Opening of - GlobeNewswire
Skye Bioscience (SKYE) price target decreased by 11.48% to 7.87 - MSN
Skye Bioscience, Inc. (SKYE) Stock Live Price, Chart & News - CoinCodex
Skye Bioscience Inc Azioni (SKYE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Skye Bioscience Inc Azioni (SKYE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Schwab Andrew J. | Director |
Aug 21 '25 |
Sale |
3.57 |
60,956 |
217,613 |
63,963 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 22 '25 |
Sale |
3.42 |
170,449 |
582,936 |
57,493 |
| 5AM Partners VII, LLC | 10% Owner |
Aug 21 '25 |
Sale |
3.57 |
60,956 |
217,613 |
63,963 |
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):